Vifor Pharma and Akebia Therapeutics Announce Expansion of Licence Agreement
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Business Wire
Expanded licence creates opportunity for vadadustat to be provided to up to 60% of U.S. dialysis patients, subject to FDA approval ZURICH--(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here:https://www.businesswire.com/news/home/20190408005804/en/ The Vifor Pharma Group (SIX: VIFN) and Akebia Therapeutics, Inc. (Nasdaq: AKBA) today announced that the companies have amended the terms of their licence agreement to sell vadadustat to Fresenius Medical Care North America dialysis clinics in the United States, subject to its approval by the U.S. Food and Drug Administration (FDA). Under the terms of the agreement signed in May 2017, Akebia granted Vifor Pharma a licence to sell vadadustat to Fresenius Medical Care North America for use solely within its dialysis clinics in the U.S., subject to FDA approval. The licence has now been amended to allow Vifor
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis [Yahoo! Finance]Yahoo! Finance
- Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on DialysisPR Newswire
- Akebia Therapeutics, Inc. (NASDAQ: AKBA) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Thinking about buying stock in Akebia Therapeutics, Boeing, Aquestive Therapeutics, General Electric, or Canoo?PR Newswire
- Thinking about buying stock in SoundHound AI, Aquestive Therapeutics, Akebia Therapeutics, Kaival Brands, or Lufax?PR Newswire
AKBA
Earnings
- 3/14/24 - Beat
AKBA
Sec Filings
- 3/15/24 - Form 8-K
- 3/14/24 - Form 10-K
- 3/14/24 - Form 8-K
- AKBA's page on the SEC website